Terms: = Breast cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Prognosis
5 results:
1. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract] [Full Text] [Related]
2. Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis.
Li X; Sun J; Hu S
Wien Klin Wochenschr; 2017 Aug; 129(15-16):558-563. PubMed ID: 28364168
[TBL] [Abstract] [Full Text] [Related]
3. Combined genetic and nutritional risk models of triple negative breast cancer.
Lee E; Levine EA; Franco VI; Allen GO; Gong F; Zhang Y; Hu JJ
Nutr Cancer; 2014; 66(6):955-63. PubMed ID: 25023197
[TBL] [Abstract] [Full Text] [Related]
4. Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer.
Fagerholm R; Sprott K; Heikkinen T; Bartkova J; Heikkilä P; Aittomäki K; Bartek J; Weaver D; Blomqvist C; Nevanlinna H
Ann Oncol; 2013 Nov; 24(11):2780-5. PubMed ID: 23897704
[TBL] [Abstract] [Full Text] [Related]
5. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.
Suspitsin EN; Sokolenko AP; Togo AV; Lazareva YR; Turkevich EA; Matsko DE; Henrich KO; Borresen-Dale AL; Schwab M; Cornelisse CJ; Imyanitov EN
Int J Cancer; 2007 Jan; 120(2):297-302. PubMed ID: 17066426
[TBL] [Abstract] [Full Text] [Related]
